Penetration of cephalosporins into bone. 1984

B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani

The penetration characteristics of cefazolin and cephradine in human bone were determined in 35 patients undergoing total knee replacement. The results were compared to previously reported data on patients undergoing total hip replacement. The time required to achieve peak bone levels in total knee replacement was less than in total hip replacement. Importantly, peak bone levels in total knee replacement (cefazolin: 11 mg/kg; cephradine: 7 mg/kg) were significantly less (less than or equal to 50%) than bone levels in total hip replacement (cefazolin: 30 mg/kg; cephradine: 23 mg/kg). The bone half-lives (t 1/2) of cephalosporins were prolonged in total knee replacement compared to total hip replacement because of the tourniquet effect. The reduction in peak bone levels and the bone t 1/2 of cephalosporins should be taken into account in patients receiving prophylaxis for total knee replacement. Therefore, patients undergoing total knee replacement should receive 2 g of a parenteral cephalosporin 30 min prior to surgery in order to achieve the same degree of protection, i. e., peak bone levels, as is achieved with 1 g of a cephalosporin administered prophylactically to patients undergoing total hip replacement. If the critical effect of the tourniquet is not taken into account in antibiotic prophylaxis for patients undergoing total knee replacement, then suboptimal bone cephalosporin levels may result.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007719 Knee Joint A synovial hinge connection formed between the bones of the FEMUR; TIBIA; and PATELLA. Superior Tibiofibular Joint,Joint, Knee,Joint, Superior Tibiofibular,Knee Joints,Superior Tibiofibular Joints,Tibiofibular Joint, Superior
D007720 Knee Prosthesis Replacement for a knee joint. Knee Prostheses,Prostheses, Knee,Prosthesis, Knee
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D006622 Hip Prosthesis Replacement for a hip joint. Femoral Head Prosthesis,Femoral Head Prostheses,Hip Prostheses,Prostheses, Femoral Head,Prostheses, Hip,Prosthesis, Femoral Head,Prosthesis, Hip
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013582 Synovial Fluid The clear, viscous fluid secreted by the SYNOVIAL MEMBRANE. It contains mucin, albumin, fat, and mineral salts and serves to lubricate joints. Synovia,Fluid, Synovial,Fluids, Synovial,Synovial Fluids

Related Publications

B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
January 1989, Reviews of infectious diseases,
B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
May 1979, Antimicrobial agents and chemotherapy,
B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
February 1996, Journal of chemotherapy (Florence, Italy),
B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
January 1989, Chemotherapy,
B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
May 1978, Lancet (London, England),
B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
May 1985, The Journal of antimicrobial chemotherapy,
B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
January 1985, Therapie,
B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
January 1965, Antimicrobial agents and chemotherapy,
B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
May 1978, Lancet (London, England),
B A Cunha, and H R Gossling, and H S Pasternak, and C H Nightingale, and R Quintiliani
June 1976, Acta orthopaedica Scandinavica,
Copied contents to your clipboard!